Advertisement

Medical Oncology

, 31:56 | Cite as

Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

  • Guoqi Song
  • William C. Cho
  • Ling Gu
  • Bangshun He
  • Yuqin Pan
  • Shukui WangEmail author
Original Paper

Abstract

The objective was to investigate the expression and prognostic value of CD59 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent rituximab-cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). The immunohistochemical expressions of CD59 in 186 well-characterized DLBCL patients were evaluated using tissue microarrays and then were related to known tumor- and patient-related variables and to survival. The results show that CD59 expressions were not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type. We also analyzed the relationships of CD59 expression with overall survival (OS) and progression-free survival (PFS) in DLBCL patients who were uniformly treated with R-CHOP. The high expression of CD59 was correlated with poor OS and PFS compared with the low-expression CD59. Our findings indicate that the CD59 level at onset is an independent predictor of the prognosis of DLBCL patients treated with R-CHOP.

Keywords

Diffuse large B-cell lymphoma (DLBCL) CD59 R-CHOP 

Notes

Conflict of interest

The author(s) confirm that this article content has no conflict of interest.

References

  1. 1.
    Swerdlow SHCE, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.Google Scholar
  2. 2.
    Habermann TM, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Friendberg Jonathan W. New strategies in diffuse large B-cell lymphoma: translating finding from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17:6112–6.CrossRefGoogle Scholar
  4. 4.
    Okamura T. A predictive model for aggressive non-Hodgkin’s lymphoma. The international Non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  5. 5.
    Hou Y, Wang HQ, Ba Y. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012;29:3498–503.PubMedCrossRefGoogle Scholar
  6. 6.
    Provencio M, et al. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51:2021–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang H, et al. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood. 2010;115:592–600.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Golay J, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–8.PubMedGoogle Scholar
  9. 9.
    Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high throughput molecular profiling of tumour specimens. Nat Med. 1998;4:844–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Torhorst J, et al. Tissue microarrays for the rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249–56.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Pfreundschuh M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Sehn LH, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Shustik J, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica. 2010;95:96–101.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Maloney DG, et al. IDEC-C2B8 (rituximab) anti-CD20monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–95.PubMedGoogle Scholar
  18. 18.
    Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30:424–33.PubMedCrossRefGoogle Scholar
  19. 19.
    You T, Hu WG, Ge XW, Shen JN, Qin XB. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. Cell Mol Immunol. 2011;8:157–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Hu WG, Ge XW, You T, Xu T, Zhang JY. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011;71:2298–307.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Ge XW, Wu L, Hu WG, Fernandes S. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:6702–11.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Golay J, Lazzari M, Facchinetti V. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Dzietczenia J, et al. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20 + non-Hodgkin’s lymphoma. Med Oncol. 2010;27:743–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Weng WK. Levy: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98:1352–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Guoqi Song
    • 1
  • William C. Cho
    • 2
  • Ling Gu
    • 3
  • Bangshun He
    • 3
  • Yuqin Pan
    • 3
  • Shukui Wang
    • 1
    Email author
  1. 1.Medical School of Southeast UniversityNanjingChina
  2. 2.Department of Clinical OncologyQueen Elizabeth Hospital, Hong KongKowloonHong Kong
  3. 3.Central Laboratory of Nanjing First HospitalNanjing Medical UniversityNanjingChina

Personalised recommendations